<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Pam Chmiel on The Business Of Cannabis on Medium]]></title>
        <description><![CDATA[Stories by Pam Chmiel on The Business Of Cannabis on Medium]]></description>
        <link>https://medium.com/@pamchmiel?source=rss-1625a0c21dce------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*f1mPB-89xQ-hgAJuAMcqpQ.jpeg</url>
            <title>Stories by Pam Chmiel on The Business Of Cannabis on Medium</title>
            <link>https://medium.com/@pamchmiel?source=rss-1625a0c21dce------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 07:54:42 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@pamchmiel/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Cannabis investors stay on sidelines despite rescheduling momentum]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://pamchmiel.medium.com/cannabis-investors-stay-on-sidelines-despite-rescheduling-momentum-08b02bc8ea1e?source=rss-1625a0c21dce------2"><img src="https://cdn-images-1.medium.com/max/1024/1*MvQTtRNC_FCD-MZhcMKSHw.jpeg" width="1024"></a></p><p class="medium-feed-snippet">First published in GreenState Magazine</p><p class="medium-feed-link"><a href="https://pamchmiel.medium.com/cannabis-investors-stay-on-sidelines-despite-rescheduling-momentum-08b02bc8ea1e?source=rss-1625a0c21dce------2">Continue reading on Medium »</a></p></div>]]></description>
            <link>https://pamchmiel.medium.com/cannabis-investors-stay-on-sidelines-despite-rescheduling-momentum-08b02bc8ea1e?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/08b02bc8ea1e</guid>
            <category><![CDATA[investment]]></category>
            <category><![CDATA[cannabis]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Thu, 04 Jun 2026 14:01:49 GMT</pubDate>
            <atom:updated>2026-06-04T14:01:49.682Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Operating in the Missouri Market with Curio Wellness]]></title>
            <link>https://pamchmiel.medium.com/operating-in-the-missouri-market-with-curio-wellness-91825d750227?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/91825d750227</guid>
            <category><![CDATA[cannabis]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Wed, 18 Mar 2026 23:21:40 GMT</pubDate>
            <atom:updated>2026-03-18T23:21:40.485Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*sD9D2ZuUn59kZgns5I2R5g.png" /></figure><p><a href="https://cannabisindustryjournal.com/feature_article/operating-in-the-missouri-market-with-curio-wellness/"><em>This article first appeared in the Cannabis Industry Journal</em></a></p><p>Missouri has quietly built one of the country’s more successful adult-use cannabis markets since launching recreational sales in 2023. Since legalization, the state has quickly grown into one of the largest cannabis markets in the Midwest, generating strong sales and supporting an expanding network of cultivators, processors, and dispensaries.</p><p>Unlike many states that see medical patient numbers decline after legalization, Missouri has continued to grow its medical program even as adult-use sales expand.</p><p>Curio Wellness, a vertically integrated cannabis company founded by the Bronfein family and headquartered in Baltimore, has been steadily expanding its presence in the state. The company first entered the Missouri market through the acquisition of a cultivation facility and broadened its retail footprint last fall with the purchase of four Greenlight Dispensaries locations.</p><p>Wendy Bronfein, Chief Brand Officer and co-founder of Curio Wellness, praised the rollout of the Missouri market, noting that while Missouri operates under a limited-license framework, the market still supports a robust number of operators and retail outlets, creating strong statewide distribution. Bronfein also touted the program’s tax structure, noting that taxes collected from the medical cannabis program are directed to a veterans’ fund that has already received tens of millions of dollars.</p><p>She added that Missouri has been notable for both clearly reporting revenues and delivering funds to its intended programs — something that does not always happen in other markets. The program’s success is particularly noteworthy, she said, given that Missouri is a traditionally conservative state, challenging assumptions that well-functioning cannabis markets only emerge in more progressive regions.</p><p>Like several other states, Missouri allows cannabis businesses to take standard business deductions on their state taxes, partially offsetting the impact of the federal Internal Revenue Code Section 280E, which continues to limit deductions for cannabis companies at the federal level.</p><h4><strong>Why Missouri?</strong></h4><p>Curio entered the Missouri market after an opportunity arose to acquire an existing medical cannabis license focused on cultivation and manufacturing. Initially, the team had not pursued Missouri because the state favored locally rooted applicants.</p><p>Bronfein noted that the largest operators in Missouri are not the typical national multi-state operators seen in other markets, but rather local businesses with strong community support.</p><p>Missouri’s location also offers strategic geographic advantages. With multiple neighboring states lacking their own programs, the state benefits from significant cross-state patient and consumer traffic, particularly in border regions. Similarly, Bronfein observed that even in Maryland, where surrounding states have some form of legal cannabis program, customers often cross state lines in search of better prices and products.</p><p>The Curio team also identified an opportunity to fill a white space in the Missouri market with wellness-oriented cannabis products. At the time, many processors were primarily focused on high-THC flower and potency-driven products, leaving relatively little focus on formulations designed around wellness and functional benefits.</p><h4><strong>Market Bottlenecks</strong></h4><p>Despite Missouri’s generally strong market performance, operators still face challenges navigating the system. According to Bronfein, one of the most significant bottlenecks is the state’s packaging approval process.</p><p>Each product design must undergo a detailed regulatory review before it can be produced, which can take 30 to 60 days. Because companies cannot confidently order packaging materials until designs receive regulatory approval, the process can slow product launches and create additional operational costs.</p><p>She also noted that regulatory interpretation can sometimes create confusion for businesses. In addition to formal statutes and regulations, operators may encounter informal guidance that functions like additional rules but does not always go through the same formal regulatory process, making it more complicated to navigate the evolving framework.</p><h4><strong>Building for the Global Future</strong></h4><p>Although Good Manufacturing Practice standards are not required in Missouri, Curio Wellness has implemented CGMP-certified processes across its operations in every state where it operates as part of a long-term strategy.</p><p>According to Rebecca Bronfein Raphael, Vice President of Business Development at Curio Wellness, the company adopted these standards early on with the expectation that cannabis would eventually fall under federal oversight similar to other consumer packaged goods regulated by the U.S. Food and Drug Administration.</p><p>By building its production systems to meet the same manufacturing standards used in the mainstream food and consumer product industries,</p><p>Curio Wellness delivers consistent quality, strong audit-ready accountability, and rigorous safety protocols across its operations. Raphael said the framework also helps standardize employee training and day-to-day operational procedures.</p><p>As federal and global cannabis regulations continue to evolve toward stricter guidelines, adopting CGMP standards positions the company ahead of the curve, particularly as many cannabis operators have yet to implement similarly rigorous manufacturing systems.</p><p>The company is also preparing for the future through its product development strategy. Curio has been investing in tablet-style cannabis products designed to resemble familiar wellness supplements and pharmaceutical formats.</p><blockquote>Raphael explained that the team is building products for where the market is heading, rather than where it currently stands. “Ultimately, our dream is to see sleep tablets on the shelves of Target, since they are more likely to sell a tablet than an eighth,” she said.</blockquote><p>Curio is also thinking carefully about the types of production methods that will support long-term scalability. Raphael explained that the company has focused much of its extraction infrastructure on CO₂ extraction, a method already widely used in food and pharmaceutical manufacturing and recognized by the U.S. Food and Drug Administration.</p><p>Curio uses this process for its Best Self wellness products because it allows the company to produce consistent formulations at scale.</p><p>At the same time, the product innovation team continues to explore emerging technologies, including scalable solventless extraction methods. While solventless products have gained popularity among cannabis connoisseurs, Raphael noted that the technology has not yet reached a level where it can be easily scaled for mass-market production.</p><p>Curio is clearly preparing for a future in which cannabis functions as a mainstream consumer packaged good. The company is focused on building systems and product formats that could eventually support large-scale retail distribution and even global markets.</p><h4><strong>Growing with Tissue Culture</strong></h4><p>Similar to its operations in Maryland, Curio cultivates its plants using tissue culture, a propagation method used by only a small number of cannabis companies. However, the method is beginning to gain broader adoption.</p><p>The technique allows the team to maintain a large and diverse genetic library while using relatively little physical space and ensuring consistent, disease-free starting material.</p><p>Curio’s decision to use tissue culture is based on its approach of borrowing proven practices from established industries rather than reinventing processes within the cannabis sector. When launching the company, the team studied how large-scale agricultural producers operate and recognized that tissue culture was already widely used in traditional agriculture.</p><p>Bronfein pointed to examples such as commercial berry producers, where companies like Driscoll’s rely on tissue culture to maintain healthy plant genetics and consistent production.</p><p>Applying this approach in cannabis has allowed Curio to maintain a secure and expansive genetic portfolio without dedicating large areas of its cultivation facility to mother plants. As a result, the company has been able to convert space that would normally house mother plants into additional production capacity.</p><p>According to Raphael, the system also gives Curio the flexibility to introduce a wide range of cultivars to the market, test consumer demand, and gather feedback before determining whether a strain remains in regular production or moves into one of the company’s premium product lines.</p><p>Because tissue culture was relatively uncommon in the Missouri market when Curio introduced it, the company worked with state regulators to explain how the system functions and how it should be inspected.</p><blockquote>“As a team, we strive to be thought leaders in the space, and this has been a crucial area for that,” said Raphael.</blockquote><h4><strong>Maintaining Tight Inventory Control</strong></h4><p>Curio operates on a perpetual harvest schedule, bringing six to eight different strains to market each week in both Maryland and Missouri. By carefully controlling the amount of product released for each strain, the team can better balance supply and demand while helping protect against price compression.</p><p>Raphael explained that this strategy also helps preserve product freshness once it leaves the cultivation facility. Rather than flooding the market with large quantities of a single strain, Curio aims to release only the volume the market can reasonably absorb in a given week.</p><p>Curio also maintains a strict 21-day inventory rule, meaning stores should not carry more product than they can sell within three weeks. This approach helps ensure customers purchase fresher cannabis rather than products that have been sitting in storage for extended periods.</p><p>Just as grocery retailers carefully manage the turnover of perishable items like produce, Curio treats cannabis as a perishable product.</p><p>“You wouldn’t buy strawberries sitting on a shelf for eight weeks,” said Bronfein.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=91825d750227" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Cannabis Retailer’s Survival Guide to 2026]]></title>
            <link>https://pamchmiel.medium.com/the-cannabis-retailers-survival-guide-to-2026-0ab8a44be051?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/0ab8a44be051</guid>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[retail]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Fri, 27 Feb 2026 14:29:23 GMT</pubDate>
            <atom:updated>2026-02-27T14:29:23.061Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*Dmoyu6qicbvGDgD7xPHRgA.png" /></figure><p><em>First published in the </em><a href="https://cannabisindustryjournal.com/feature_article/the-cannabis-retailers-survival-guide-to-2026/"><em>Cannabis Industry Journal</em></a></p><p>2025 saw most businesses scrutinizing their operations to trim margins and survive the tumultuous market. 2026 is about digging deeper to uncover hidden costs that will further improve their bottom line.</p><p>Tom Zuber, partner at Zuber Lawler, led a panel discussion at the recent IgniteNJ event, where experts offered advice on margin discipline and where to cut costs.</p><h4>What to Consider When Entering A New Market</h4><p>Trent Woloveck, Chief Strategy Officer at Jushi Holdings, says retailers entering a new market must evaluate three core cost centers: labor, compliance, and real estate.</p><p>Operators should closely analyze traffic patterns, peak hours, and staffing models to understand true operating costs and potential revenue. Retail, he notes, is a people-centric business where customer experience cannot be sacrificed, even in a margin-compressed environment.</p><p>Engaging with local authorities and community leaders is essential for educating lawmakers and shaping favorable, reasonable legislation. Woloveck emphasizes the importance of being a responsible operator so that regulators do not feel as though the sky is falling simply because they legalized medical and/or adult-use cannabis.</p><p>When it comes to real estate, Woloveck stresses the importance of a “main on main” location with high traffic counts, adequate parking, and strong signage, while keeping rent between 3% and 5% of total projected revenue as a benchmark for profitability. He acknowledges that securing prime locations remains one of the harder costs to control, largely because many landlords near malls or carrying mortgages on their properties are still unwilling to lease to cannabis operators. Woloveck is optimistic that federal rescheduling will expand that pool of willing landlords, increasing supply and putting downward pressure on rents. He draws a parallel to COVID-era lease concessions that proved beneficial for operators in markets like Virginia.</p><h4>Battling Price Compression</h4><p>While retailers are combating price compression that is driving down basket size, Travis Scadron, EVP at Surfside, suggests other ways to increase margins by passing merchandising costs onto brands and monetizing the real estate on your website. He cites Amazon as an example, noting that 68% of the profit on Amazon’s e-commerce platform comes from advertising sales. He stressed the importance of pushing the right products at the right time and with the right pricing.</p><p>Trip McDermott, COO of Verano, a vertically integrated operator, says the company is seeing margin erosion across all areas of the supply chain. He specifically pointed to cultivation, noting that labor prices are rising, as are input costs such as salts, nutrients, and coco. On the retail side, he said labor costs are also increasing, compounded by mounting pressure to discount.</p><p>“So, there’s erosion happening everywhere, but it’s where you can control part of that erosion, which is going to be around reducing turnover of your employees, trying to get more out of them, continuous training so you’re not having to rehire, improving efficiencies so that you’re getting more units per head out of all those employees,” he advised. “Automate where you can without sacrificing quality, and really look into the data to understand where there’s opportunity for improvement,” he added.</p><p>McDermott highlighted extraction processes as an area where costs are easily overlooked. Operators who are not capturing data on their extraction yields may be quietly eroding their margins without realizing it. Key questions to ask include: What are your inputs? Is it trim or flower? What are the yields on the other end of the extraction process? “I would say that’s an area for improvement, a lot of operators should really focus on,” said McDermott. “Capturing that data is not only important for fully understanding your cost of goods, but it also adds up to a lot of money at the end of the day.”</p><h4>Customers First</h4><p>Krista Raymer, Chief Strategy Officer at C3 Industries, cautions operators against cutting costs in areas that directly impact the customer experience. In a market where a core group of loyal customers drives the bulk of transactions, she argues that retaining existing customers is just as important as acquiring new ones. Labor reductions, shifts in inventory assortment, and changes to the marketing mix can all have unintended consequences for the in-store experience if not carefully considered in advance.</p><h4>The Hidden Risks of Inventory</h4><p>On the inventory side, Raymer warns that carrying costs can quietly balloon as operators chase newness and freshness to satisfy customer demand, which does not always align with how quickly the product actually moves. Maintaining analytical control over inventory is critical to avoiding dollars tied up in slow-moving product. Tom Zuber echoed the point, noting that buyers need to stock what actually sells and not be influenced by vendor friendships. If a brand does not meet customer expectations, it will sit on the shelf as dead weight, becoming a direct drag on the store’s bottom line.</p><p>Verano’s McDermott adds another dimension to the inventory conversation, pointing to product costing at the facility level as one of the most under-invested areas in the industry. He argues that implementing an ERP system to accurately understand the true cost of producing each product is foundational to becoming a fully dialed-in operator. The process is not easy, but McDermott says it will identify weaknesses and pinpoint where products are underperforming, providing direction for SKU rationalization. Without that level of product cost of goods, he warns, operators are likely working from their gut, which is further off than they realize.</p><h4>Flexibility and Market Pivots are Key</h4><p>Woloveck notes that rather than spreading thin across many markets, Jushi has shifted its strategy toward going wider and deeper in select states, pulling back on store expansion after a 40% increase in store count and redirecting dollars toward cultivation buildouts in high-opportunity markets like Virginia and Pennsylvania. He noted that this “concentrate and win” approach has become a common strategy across both public and private MSOs.</p><p>On vertical integration, the panelists offered contrasting views. Verano’s McDermott says that being vertically integrated in New Jersey has been an advantage, allowing the company to capture margins at every stage and bring new products to market where it can be more price-competitive in the wholesale space, particularly as newer brands use price as a competitive weapon.</p><p>Raymer says the company assesses each operation state by state and that vertical integration is not a one-size-fits-all strategy. In New Jersey, C3 operates without vertical integration, and Raymer says that works because it allows them to experiment with the market without operational pressure. In Missouri, by contrast, the company is fully vertical, targeting a set percentage of its own product through retail. As wholesale costs evolve and markets mature, she suggests the evaluation around vertical integration will continue to shift. “It just depends on where the state is, both from a cost to produce, as well as what the wholesale costs look like within that market,” she said.</p><h4>Looking at Product Margins From Different Angles</h4><p>Raymer says C3 Industries looks at inventory and assortments within a state and then by store to identify where there is room to push on margin or negotiate costs based on factors like sales velocity. The company uses markup strategies based on how quickly a product moves through the environment, focusing on total margin dollars rather than margin as a percentage.</p><p>Woloveck has observed a notable consumer shift toward larger units, with customers trading up from eighths to quarters or ounces on flower, and vape formats growing from 0.3 grams to 2 grams. Larger pack sizes lower the cost per unit and improve overall margin dollars, even if total unit count decreases. He stressed that every state, and even a city or jurisdiction within a state, requires its own distinct strategy.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=0ab8a44be051" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What Cultivators Are Talking About in New Jersey]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://pamchmiel.medium.com/what-cultivators-are-talking-about-in-new-jersey-cc87885a3d79?source=rss-1625a0c21dce------2"><img src="https://cdn-images-1.medium.com/max/768/1*TkflgetsBbWyn8ZFTL4PVg.png" width="768"></a></p><p class="medium-feed-snippet">Inside the minds of New Jersey&#x2019;s top cultivators</p><p class="medium-feed-link"><a href="https://pamchmiel.medium.com/what-cultivators-are-talking-about-in-new-jersey-cc87885a3d79?source=rss-1625a0c21dce------2">Continue reading on Medium »</a></p></div>]]></description>
            <link>https://pamchmiel.medium.com/what-cultivators-are-talking-about-in-new-jersey-cc87885a3d79?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/cc87885a3d79</guid>
            <category><![CDATA[new-jersey]]></category>
            <category><![CDATA[cultivation]]></category>
            <category><![CDATA[cannabis]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Mon, 23 Feb 2026 17:51:23 GMT</pubDate>
            <atom:updated>2026-02-23T17:51:23.519Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[The Latest CBD Scientific Research From Western Washington University]]></title>
            <link>https://pamchmiel.medium.com/the-latest-cbd-clinical-research-from-western-washington-university-e7eab1cfaa44?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/e7eab1cfaa44</guid>
            <category><![CDATA[research]]></category>
            <category><![CDATA[autism]]></category>
            <category><![CDATA[epilepsy]]></category>
            <category><![CDATA[scientific-research]]></category>
            <category><![CDATA[cannabis]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Sat, 07 Feb 2026 22:54:24 GMT</pubDate>
            <atom:updated>2026-02-08T00:20:33.476Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*h4SppCYiiAhB3a4i22-LIQ.png" /></figure><p><em>First published in the </em><a href="https://cannabisindustryjournal.com/feature_article/the-latest-cbd-clinical-research-from-western-washington-university/"><em>Cannabis Industry Journal</em></a></p><p>Josh Kaplan, PhD, is a neuroscientist and associate professor in the Behavioral Neuroscience program at Western Washington University, where his lab focuses on optimizing cannabidiol (CBD) based medicines for pediatric conditions. His work examines not only CBD’s therapeutic potential, but also its long-term developmental effects on the brain, an area of growing importance as cannabinoid therapies move deeper into clinical use.</p><p>Kaplan’s interest in CBD research began in 2015, when he was asked to evaluate Epidiolex in a mouse model of pediatric epilepsy. The treatment produced significant seizure reduction in cases where other medications had failed. The results were striking and sparked his interest in a deeper investigation of CBD and how it might work in other pediatric conditions.</p><p>While different medical conditions require different dosing, Kaplan’s lab is also exploring whether the same medication or formulation could be effective across a range of symptoms by adjusting the dose. “Can we improve CBD-based medicine by expanding that dose window so that, regardless of whether you are trying to treat epileptic seizures or improve social behaviors and communication deficits, a single formulation could be effective?” explained Kaplan.</p><p>The team evaluates CBD’s effects by modeling specific behaviors in mice, including anxiety, depression, and social interaction. By testing a wide range of doses, they can pinpoint where therapeutic effects emerge and where they fade.</p><h4>Stress, Brain Development, and CBD</h4><p>The lab also takes a bottom-up research approach, examining what is happening inside the brain at the cellular level. Many pediatric neurological conditions, including epilepsy and autism, are associated with altered protein expression and disrupted communication between neurons. Kaplan’s team applies CBD, sometimes in combination with terpenes such as beta-caryophyllene and linalool, to examine how these compounds affect molecular signaling and neuronal communication.</p><p>The lab uses live slices of mouse brain tissue outside the body and recreates the brain’s natural environment with oxygen, glucose, and essential ions. Researchers can keep neurons alive for hours and directly measure their electrical activity using electrodes. This technique allows the team to observe how CBD alters communication in specific brain regions tied to different conditions.</p><p>For example, the hippocampus, often implicated in seizures, can be studied to assess whether CBD dampens excessive neural excitation. Other regions, such as the amygdala and prefrontal cortex, are examined for changes related to anxiety, depression, and cognitive function.</p><p>“What is CBD doing there?” asks Kaplan. “We can zoom in on specific regions of the mouse brain and start manipulating them with CBD and other terpenes to see how it alters those communication patterns, which are known to change in characteristic ways across different neurological conditions.”</p><p>He explains that with epilepsy or autism, there is a shift in the brain’s balance toward excessive excitation and signaling that can lead to seizures, hypersensitivities, and certain repetitive behaviors characteristic of autism.</p><p>“We can see that actually playing out in the cellular communication patterns that we’re observing. Then we might explore what CBD is doing on those patterns. What is beta-caryophyllene doing? What happens when you put them together? That’s the approach we’re taking,” Kaplan said.</p><h4>Proving the Entourage Effect</h4><p>While anecdotal evidence around the entourage effect is widespread, there is little clinical validation, particularly for combinations of CBD and terpenes rather than THC-based formulations. Kaplan’s lab is beginning to generate early preclinical data indicating promising results for targeted, custom CBD and terpene formulations.</p><p>Previous research has shown that repeated stress or trauma during critical developmental periods can alter brain connectivity, leading to long-term behavioral and mental health challenges. In a recent, unpublished preclinical study, Kaplan’s team examined whether CBD could remedy early stress-related effects on brain development. Using an established animal model, the researchers induced early life stress and observed measurable changes in proteins involved in how brain cells connect and communicate.</p><p>Following stress exposure, the mice were treated with either CBD alone, beta-caryophyllene alone, or a combination of the two. Neither compound on its own produced meaningful changes in altered protein expression. However, when CBD and beta-caryophyllene were administered together, the combination effectively reversed the stress-induced molecular disruptions.</p><p>These findings suggest that cannabinoids and terpenes interact with distinct receptors and signaling proteins, influencing neuronal circuits and communication between brain regions. Kaplan emphasizes that cannabinoids do not “activate” one another; rather, their parallel actions converge to produce coordinated effects across neural networks. This framework helps explain the benefits of combined CBD and terpene treatments, highlighting how multi-target strategies can modulate brain function more effectively than single compounds alone. It is an early step toward understanding which compound combinations and dosing strategies are most effective for specific conditions.</p><p>Some studies suggest that removing the olfactory component — such as when terpenes are consumed in edibles — may diminish their effects. Could these benefits be mediated, at least in part, through olfactory processing, which is known to influence emotion and mood? “Why do people wear cologne or perfume? Why do we have scented candles? It makes us feel relaxed and comfortable,” said Kaplan. While earlier experiments demonstrated clear effects with oral ingestion, Kaplan believes that each method of consumption may have its own benefits.</p><h4>Activating Endocannabinoid Expression</h4><p>Another line of research in Kaplan’s lab examines how different cannabis components influence endocannabinoid expression. Anandamide, often referred to as the “bliss” molecule, is an endogenous cannabinoid that activates the brain’s cannabinoid receptors and plays an important role in mental health and well-being.</p><p>In autism, children often have lower levels of anandamide, and raising those levels may lead to improved social behaviors and communication, as well as other quality-of-life measures. Kaplan’s lab tested whether CBD alone would alter anandamide levels using a mouse model of autism spectrum disorder and measured outcomes using mass spectrometry.</p><p>They found that CBD and beta-caryophyllene increased anandamide levels on their own. “You put the two together and think you’ll get a massive effect,” Kaplan explained. “Actually, they contradicted one another and led to a reduction.”</p><p>He added, “The most exciting part about this field is the complex profile of how these different chemicals are working, the targets they’re acting on in the brain and body. But it also creates a challenge, because it’s not as straightforward as we think.”</p><h4>Are Some Terpenes More Effective Than Others?</h4><p>Kaplan’s lab began its terpene investigations with beta-caryophyllene, which is widely considered the only terpene known to directly interact with the endocannabinoid system. It can activate CB2 receptors in a manner similar to endogenous cannabinoids such as anandamide and 2-AG, as well as THC.</p><p>While Kaplan’s team has observed therapeutic benefits from beta-caryophyllene, they are also examining other common terpenes, including linalool, myrcene, and compounds found in hops and lemongrass. Among these, linalool has emerged as a standout in preclinical testing, showing strong anxiolytic effects, particularly in behavioral models of anxiety.</p><p>Kaplan’s research has also revealed pronounced sex based differences in terpene response. In one published study, mice were exposed to vaporized linalool or myrcene for short periods. Female mice consistently showed reduced anxiety and actively sought out the terpene exposure. Male mice, by contrast, initially avoided it and displayed heightened anxiety under longer exposure conditions.</p><p>When exposure time was reduced to a single brief dose, male mice exhibited the same anxiety-reducing benefits as females. The findings suggest that females may be less sensitive to terpene intensity or odor, while males may reach sensory saturation more quickly. These differences highlight dosing and exposure thresholds as critical variables in terpene-based formulations.</p><p>Kaplan’s lab is also exploring the biological mechanisms underlying these sex specific responses, with a particular focus on estrogen. Existing evidence indicates that estrogen modulates the endocannabinoid system, and Kaplan’s team has found that CBD increases anandamide levels in the brain more strongly during periods of elevated estrogen. This hormonal influence may help explain why cannabinoids and terpenes produce different effects across sexes and hormonal cycles.</p><h4>What’s Next for Kaplan’s Lab?</h4><p>With foundational studies now established, Kaplan is turning his attention to deeper molecular and physiological mechanisms to better understand what is happening beneath the surface and to help inform more reliable cannabinoid-based medicines.</p><p>One key area of investigation is the gut-brain axis. Kaplan’s team is exploring how CBD and related compounds influence the gut microbiome and immune signaling, both of which play a critical role in regulating brain inflammation and neurological health. To do this, the lab is collaborating with immunology and microbiome expert Annalise Snyder at Western Washington University to characterize how cannabinoid based therapies affect immune responses in the brain that may contribute to disease pathology.</p><p>The lab is also integrating computational neuroscience into its research strategy. In collaboration with computational neuroscientist Cam Harris, Kaplan’s team is using brain network modeling to simulate how different brain regions communicate and how cannabinoids and terpenes alter those signaling patterns. These models are designed to predict which compound combinations are most likely to be effective for specific conditions, such as epilepsy or autism, before moving into experimental testing.</p><p>Rather than testing an overwhelming number of possible cannabinoid and terpene combinations, the team can narrow the field to the most promising formulations using advanced predictive modeling, thereby providing a more precise approach for cannabinoid medicine.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e7eab1cfaa44" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Inside Iconic Tonics’ Vision for Building Enduring Cannabis Beverage Brands]]></title>
            <link>https://pamchmiel.medium.com/inside-iconic-tonics-vision-for-building-enduring-cannabis-beverage-brands-3904fb3254d4?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/3904fb3254d4</guid>
            <category><![CDATA[functional-ingredients]]></category>
            <category><![CDATA[non-alc]]></category>
            <category><![CDATA[non-alcoholic]]></category>
            <category><![CDATA[infused-beverages-market]]></category>
            <category><![CDATA[beverage]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Tue, 03 Feb 2026 16:35:28 GMT</pubDate>
            <atom:updated>2026-02-03T16:42:12.055Z</atom:updated>
            <content:encoded><![CDATA[<p><em>What beverage operators can learn from Snoop Dogg’s brand.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/768/1*Dk-XCjGto6M0PV5W73sskA.png" /></figure><p><a href="https://cannabisindustryjournal.com/feature_article/inside-iconic-tonics-vision-for-building-enduring-cannabis-beverage-brands/"><em>First published in the Cannabis Industry Journal</em></a></p><p>A wave of infused beverage brands flooded the market over the last few years. Now, the sector has entered a period of settling and reassessment, as operators pause to evaluate the real opportunity and determine the smartest path forward amid ongoing legal uncertainty.</p><p>While adult-use cannabis markets continue to struggle with launching beverage brands for structural reasons, states without adult-use dispensaries are normalizing THC consumption under the radar through hemp beverages in everyday social settings. Bars, restaurants, music venues, and event spaces are increasingly embracing hemp drinks as a familiar, socially acceptable option. Minnesota helped pave the way for normalizing THC consumption outside of dispensaries, and cities like Austin, Nashville, and Atlanta are following suit by allowing hemp beverages in traditional social environments.</p><p>To understand how seasoned operators are thinking about the new year, I spoke with Evan Eniman, one of the founding members of Snoop Dogg’s Casa Verde venture capital firm and a partner in the beverage company Iconic Tonics. Iconic Tonics represents Snoop’s Do It Fluid and Doggie Spritz beverages, as well as the Klaus brand from well-known mixologist Warren Bobrow. Eniman shared how the team is thinking about brand building, product development, and long-term strategy heading into the new year.</p><h4>Your Story Matters</h4><p>The most common advice from branding experts is simple: tell a story.</p><p>Snoop Dogg’s drink line is built around his decades-long legacy in cannabis culture. The Klaus brand’s reputation in the cocktail world brings a different, but equally intentional, narrative to the portfolio.</p><p>As Eniman explains, “It’s Warren’s craft and his creativity around all things beverage that really stands out. His products are meant to come from a true cocktail experience, using unique ingredients and pairing them in a way that tells a story. Every drink tells a story, whether it’s about the ingredients, how it’s prepared, or who you’re sharing it with.”</p><p>Bobrow formulates products aimed at regional preferences, tailoring flavor profiles to the tastes, interests, and cultural references of each market. In New York, the Klaus line has performed especially well, even with little marketing support. According to Eniman, that success reflects how closely the formulation’s sophistication aligns with New Yorkers’ palates.</p><p>“I think about everything from the perspective of the user and the occasion,” Eniman says. “The brand has to live in that experience with the consumer.”</p><h4>Finding the Right Cultural Partner to Connect With Consumers</h4><p>With traditional cannabis marketing heavily restricted, brands are forced to think creatively about how they reach consumers.</p><p>“We look for culture fit partnerships as a way to connect with consumers who are already seeking these ingredients, formats, and experiences,” Eniman says.</p><p>Those partners might be restaurants, live music venues, or other spaces where education and discovery about cannabis drinks can happen naturally and fit into social occasions.</p><p>For example, Iconic Tonics recently partnered with The Butcher’s Daughter and its music listening bar concept, Only The Wild Ones, with locations in New York, Austin, and Los Angeles. They launched Warren Bobrow’s terpene-only drink, Nein, to play into the non-alc movement taking over bars.</p><p>“Their entertainment arm, Only The Wild Ones, made it a natural fit. Now the drink lives on the menu, and consumers can experience a ready-to-drink cocktail infused with botanical terpenes in a setting that matches the culture,” explains Eniman.</p><p>By embedding the product within an established lifestyle brand, Iconic Tonics can introduce consumers to terpenes through a more natural process rather than heavy, education-focused marketing.</p><h4>A Slow and Measured Approach to Market</h4><p>Many beverage brands are racing to market, prioritizing early scale and short term revenue growth to satisfy investors. Iconic Tonics is taking a different path.</p><p>The company is intentionally moving low and slow, placing brand development and long term relevance ahead of rapid expansion.</p><p>Eniman has been observing and participating in the functional ingredients market since its earliest days and believes the category is still in its infancy. “We are barely scratching the surface of what functional beverages are,” he says. “There’s another 40 years of category building ahead of us, including infused beverages.”</p><p>“These are moments in time where real brand legacies are built,” Eniman continues. “They are opportunities to change consumer behavior, routines, and expectations. Functional beverages represent far more than what we are currently seeing.”</p><h4>The Tip of the Iceberg for Functional Ingredients</h4><p>Eniman sees terpenes as only one entry point into a much broader functional beverage ecosystem. While hemp, particularly THC, dominates the market due to strong consumer demand, it is also creating a pull for more differentiated functional products.</p><p>“Many hemp brands today are simply THC brands,” Eniman says. “That’s who they are. That’s what they do. But when the landscape shifts, they realize they may not actually have a brand or even a business.”</p><p>Iconic Tonics has been experimenting beyond cannabinoids with ingredients like Kanna, a succulent plant native to South Africa that has been used for centuries for mood elevation and stress relief.</p><p>Kanna is part of the company’s partnership with The Butcher’s Daughter, where it is being introduced in New York, Los Angeles, and Austin. While still largely unknown to U.S. consumers, Eniman points to the significance of kanna’s deep cultural and historical roots in crafting stories that help build brands.</p><p>“These ingredients are similar to cannabis in that they’ve been used for thousands of years in different cultures,” he explains. “They’re finally taking hold here, much like other superfoods that entered the U.S. market over time.”</p><p>For Eniman, it’s less about chasing market size and more about connecting consumers to purpose-driven consumption. Just as people drink coffee for energy or turn to adaptogens for mental balance, functional beverages will increasingly be chosen based on desired effect and occasion.</p><p>“The size of those markets is unknown,” Eniman says. “But the function of what you’re drinking, the access to it, and the availability are shifting rapidly. That’s what’s exciting right now.”</p><h4>Hemp Offers Strategic Advantages</h4><p>For beverage brands, hemp currently offers strategic advantages that the regulated market cannot match. The ability to build awareness beyond state borders, access traditional retail channels, and experiment with formulation at scale makes hemp a more attractive platform for brand development.</p><p>Regulated cannabis beverages remain constrained by limited sales channels, fragmented manufacturing and distribution requirements, and operational costs that make true craft formulations difficult to sustain. Cold chain challenges, additional taxation, and minimal retail shelf space further limit growth.</p><p>Hemp, by contrast, allows brands to plan and execute nationally or selectively across key markets while reaching consumers in familiar settings like liquor stores, convenience stores, restaurants, and event venues.</p><p>“Beverage brands aren’t putting serious money into the regulated cannabis space right now because they can build in hemp,” Eniman says. “It’s the same cannabis consumer, but with a much wider audience.”</p><p>As the infused beverage category continues to mature, Iconic Tonics is focused less on chasing trends and more on building brands that can adapt, evolve, and endure.</p><p>In Eniman’s view, the infused beverage category still has work to do on formulation, education, and normalization. In a fragmented cannabis landscape, a careful, long-term approach may be the strongest competitive advantage.</p><p>Listen to Evan’s full interview on the <a href="https://innovating-cannabis-podcast.simplecast.com/episodes/173-inside-snoops-beverage-company-with-evan-eneman">Innovating Cannabis Podcast.</a></p><p>also available on <a href="https://www.youtube.com/watch?v=rTizA7A2ypU">YouTube.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3904fb3254d4" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Case For Cannabis Telemedicine: Can it Work in the US?]]></title>
            <link>https://pamchmiel.medium.com/the-case-for-cannabis-telemedicine-can-it-work-in-the-us-554a9ffd0300?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/554a9ffd0300</guid>
            <category><![CDATA[telemedicine]]></category>
            <category><![CDATA[germany]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Wed, 28 Jan 2026 19:07:06 GMT</pubDate>
            <atom:updated>2026-02-09T16:13:56.538Z</atom:updated>
            <content:encoded><![CDATA[<p><em>A Look at the Bloomwell Group’s German Business Model</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*IlOsUvOLXjw3YYD5oya3Ig.png" /></figure><p>This article was first published in the <a href="https://cannabisindustryjournal.com/feature_article/the-case-for-cannabis-telemedicine/">Cannabis Industry Journal</a></p><p>It has been one year since Germany fully legalized cannabis on April 1, 2025, following the launch of its medical program in 2017. While cannabis was removed from the narcotics list, Germany continues to take a medical-first approach. Few expect full adult-use legalization anytime soon, particularly after a conservative government was elected last year.</p><p>According to Dr. Julian Wichmann, CEO of Bloomwell Group, Germany’s leading cannabis telemedicine platform, the market still has enormous growth potential. He estimates that fewer than 10 percent of Germans are even aware that a legal medical cannabis program exists.</p><p>Germany is effectively creating the blueprint for the European Union’s cannabis framework through its telehealth system. Cannabis is prescribed by a physician, dispensed by a pharmacy, and shipped directly to the patient’s home. Patients do not need to be physically present, a model that has dramatically expanded access while maintaining medical oversight.</p><p>At the same time, Germany’s social clubs, which allow groups to collectively cultivate cannabis for personal consumption, have struggled to deliver a reliable supply. Several clubs have reported failed harvests, forcing them to discard entire crops. Many operations lack agricultural expertise and operational efficiency, and in some cases, the cost of club-grown cannabis exceeds medical market pricing. With supply abundant and prices low, medical cannabis currently sells for as little as three euros per gram, making it a more consistent and affordable option for many consumers.</p><h4>Bad Actors Outside of Germany</h4><p>European law allows online businesses to operate across borders within the EU, and cracks are beginning to appear in the telemedicine system. According to Wichmann, bad actors operating from outside Germany have entered the market, exploiting regulatory gaps. Because these companies are not physically based in Germany, they are not fully subject to German law, making enforcement difficult.</p><p>In one recent case, a data breach was exposed, but German authorities were limited in their ability to intervene. To address this issue, Wichmann says regulators are now considering new rules that would require cannabis telemedicine providers to be physically established in Germany.</p><h4>Cannabis Is Reviving German Pharmacies</h4><p>Germany’s pharmacy sector has been under intense pressure for years, facing rising operating costs and stagnant government reimbursement rates. As a result, pharmacies have been closing at an alarming pace, particularly in rural areas. In 2025 alone, Germany recorded 502 pharmacy closures and just 62 new openings, leaving 16,601 pharmacies nationwide. That is the lowest number since 1977.</p><p>The demographic challenge is equally severe. Many pharmacy owners are between 65 and 70 years old and struggle to find successors. Younger pharmacists often opt for higher-paying roles in industry rather than taking on the financial risk of running a community pharmacy.</p><p>Medical cannabis has helped reverse that trend. Most German pharmacies are independent, family-owned businesses, and many are now hiring staff, expanding their facilities, and serving up to 1,000 cannabis patients per day. For a sector that has been financially battered, cannabis has become a genuine comeback story.</p><p>There are no multinational corporations shipping medical cannabis directly into Germany. All products must go through licensed German pharmacies. “For many pharmacies, this was a completely new sector,” Wichmann says. “The knowledge and logistics they’ve developed are truly impressive.”</p><h4>A Telemedicine Shutdown Looms</h4><p>Despite the sector’s growth, prohibition-minded policymakers continue to threaten restrictions on telemedicine and mail delivery. While no final decision has been made, Wichmann says signs of compromise are emerging.</p><p>“I think we’re going to see a solution that regulates the sector but also provides stability so it can continue to grow,” he says.</p><p>Surprisingly, no centralized cannabis patient registry exists anywhere in the EU, even though the International Narcotics Control Board requires them. Wichmann estimates that just over one million patients receive at least one cannabis prescription per year, a figure he considers far too low. “I think that number should increase tenfold over the next two to three years,” he says.</p><h4>Telemedicine Connects Doctors, Pharmacies, and Patients</h4><p>According to Dr. Julian Wichmann, one of the biggest barriers to medical cannabis access in Germany is not regulation but the lack of physician participation. Even after legalization and the rise of telemedicine, many local doctors still do not prescribe cannabis, particularly those operating within statutory health insurance systems. In some cases, physicians are more willing to prescribe opioids and may even require patients to try them before considering cannabis, despite opioids’ well-documented risks and addiction potential.</p><p>Wichmann argues that this hesitation stems from a lack of education and hands-on experience. Prescribing cannabis is one thing, but having the knowledge and expertise to care for hundreds or even thousands of cannabis patients requires specialized training.</p><p>Patients do not receive a medical card in Germany’s telemedicine model. A valid prescription is sufficient. Through platforms like Bloomwell, patients can access licensed physicians either digitally or in person, complete consultations, and receive prescriptions that specialized pharmacies can fill. Wichmann says many patients already understand their conditions and only need limited initial interaction, with more meaningful questions arising weeks or months into treatment once they have tested the product.</p><p>Digital care allows patients to revisit guidance, dosing recommendations, and educational resources over time, something that is difficult in traditional healthcare settings where new patient visits may last only two to three minutes. With telemedicine, patients typically see a doctor every four weeks. In contrast, in traditional German healthcare, patients may wait three months for a prescription renewal. Critics argue that telemedicine lowers the barrier too far, but Wichmann believes longer onboarding alone does not make cannabis safer.</p><p>Access to pharmacies remains another challenge. Although all German pharmacies are legally required to fill cannabis prescriptions, fewer than 10 percent currently do so in practice. Telemedicine platforms play a key role in connecting patients with pharmacies that specialize in cannabis, allowing prescriptions to be filled and delivered, often within 48 hours.</p><p>With more than 400 cannabis strains and product formats available, Wichmann says cannabis does not fit neatly into conventional healthcare models. Telemedicine, he argues, reflects how patients actually manage cannabis treatment over time.</p><h4>Telemedicine Does the Heavy Lifting for Doctors</h4><p>Telemedicine has significantly improved physician efficiency, allowing doctors to care for far more cannabis patients than would be possible in traditional settings. According to Wichmann, Bloomwell developed its own government-approved e-prescription infrastructure because no standardized system existed in Germany. The platform was designed to meet both legal and logistical requirements, reducing administrative burden and enabling doctors to manage patient care at scale.</p><p>As a result, physicians on the platform can responsibly oversee thousands of patients over the course of a year, even as medical cannabis remains a bottleneck due to limited clinical expertise. Cannabis education is still absent from medical school curricula, leaving most doctors to develop knowledge independently. Bloomwell provides structured onboarding and education for physicians entering the space.</p><p>Technology is increasingly central to clinical decision-making. With hundreds of cannabis products available and frequent supply changes, determining the most appropriate product or strain for a specific patient remains complex. Wichmann believes data-driven tools and algorithms will be critical to improving consistency and outcomes, particularly as current prescribing practices rely heavily on anecdotal evidence rather than large-scale analysis.</p><p>While AI-driven clinical insights are a long-term goal, Bloomwell’s immediate focus remains operational reliability. Ensuring seamless coordination among patients, doctors, pharmacies, and logistics providers remains the primary challenge. As regulations continue to evolve, workflows may need to adapt, but Wichmann views the company’s growing data capabilities as both a responsibility and a foundation for future clinical innovation in the cannabis industry.</p><h4>The Pharmacy Compounding Debate</h4><p>Although some manufacturers argue that pharmacy compounding introduces unnecessary risk, Wichmann disagrees. In Germany, pharmacists are still required to compound medical cannabis because the product is technically prescribed off-label. Even when the process involves little more than weighing and repackaging, it is legally considered a pharmaceutical preparation.</p><p>According to Wichmann, pharmacies that specialize in cannabis have adapted by building larger, more efficient facilities to streamline compounding workflows. Rather than limiting innovation, the system has enabled the development of a wider range of cannabis formulations beyond flower, including liquids, oral preparations, and other dosage forms prepared directly in pharmacies.</p><p>Wichmann argues that pharmacy compounding adds an additional layer of quality control. Cannabis products are tested again at the pharmacy level, and German pharmacies are subject to strict audits. Despite the extra step, prices remain competitive and, in many cases, lower than those on the illicit market. He believes the model ultimately makes medical cannabis safer and more accessible for patients.</p><p>Bloomwell is expanding its services by offering pharmacy pickup and enhancing last-mile delivery options, in addition to shipping, ensuring patients can access their medication quickly while keeping pharmacies central to the supply chain.</p><p>Germany is miles ahead of the US in establishing a functional framework for cannabis medicine. It is a model that US policymakers should study closely.</p><p>Listen to Dr. Julian Wickmann’s full interview on the <a href="https://innovating-cannabis-podcast.simplecast.com/episodes/178-building-the-german-cannabis-marketplace">Innovating Cannabis Podcast.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=554a9ffd0300" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Are Triploids The Next Big Thing In Cultivation?]]></title>
            <link>https://pamchmiel.medium.com/are-triploids-the-next-big-thing-in-cultivation-c2e691e4c5dc?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/c2e691e4c5dc</guid>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[plants]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[cultivation]]></category>
            <category><![CDATA[seeds]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Sun, 25 Jan 2026 21:58:00 GMT</pubDate>
            <atom:updated>2026-01-25T21:58:00.224Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*ziop_TgAg9CMir7m_lgPDQ.png" /></figure><p><em>This article was first published in the </em><a href="https://cannabisindustryjournal.com/?post_type=feature_article&amp;p=38352"><em>Cannabis Industry Journal</em></a></p><p>It all starts with genetics. The possibilities for manipulating the cannabis plant through breeding and cultivation are expanding rapidly, and advancements in methods for achieving optimal plant expression are accelerating as the industry moves into 2026. Breeders and cultivators are increasingly banding together to share knowledge and resources, while high-tech equipment and analytical tools are being deployed to deepen understanding of the plant’s biochemistry.</p><p>As cultivation operations scale, operators are looking for ways to achieve higher yields, stronger plant vigor, improved disease resistance, and, most importantly, consistent outcomes from plant to plant. One approach is polyploid breeding, specifically the development of triploid cannabis plants.</p><p>John Keating, founder of <a href="https://traplinegenetics.com/">Tesoro Genetics</a> and leader of the genetics program at Advanced Nutrients, has been at the forefront of this effort. While triploids are widely used in large-scale agriculture, most consumers unknowingly encounter them in seedless fruits like watermelon and bananas. The approach remains relatively new to the cannabis industry and far from simple to execute.</p><p>According to Keating, his team spent several years refining the process before achieving reliable results and launching a line of triploid seeds at MJBiz 2025. I sat down with him to better understand how triploid cannabis works, why it matters for commercial cultivation, and what it could mean for the future of genetic innovation in the industry.</p><p>To understand why triploids are gaining traction, it helps to start with a basic explanation of ploidy.</p><h4>Diploids, Triploids, and Tetraploids — Explained</h4><p>Most plants, including cannabis, are diploid, meaning they carry two sets of chromosomes (2N) — one inherited from each parent, Keating explains. Each chromosome contains genes, and each gene exists in two copies, known as alleles, which influence traits such as plant morphology, cannabinoid production, and secondary metabolite expression.</p><p>During normal reproduction, a diploid plant produces gametes — pollen and ovules — that each contain a single set of chromosomes (1N). When pollen and ovule fuse during fertilization, those chromosome sets recombine, restoring the diploid state (2N) in the embryo.</p><p>“That’s the standard biological cycle,” Keating says. “You split the genetic material in half to make gametes, then bring it back together to rebuild the diploid organism.”</p><p>Polyploid breeding intentionally disrupts that cycle.</p><p>According to Keating, breeders can induce chromosome doubling in a diploid plant to create a tetraploid (4N) plant with four sets of chromosomes. Crossing that tetraploid with a standard diploid produces a triploid (3N) offspring.</p><h4>Why Extra Chromosomes Matter</h4><p>Changing the number of chromosome sets has immediate effects at the cellular level.</p><p>Polyploid plants, particularly tetraploids, have larger cells than diploid plants, Keating explains. Larger cells often correlate with larger leaves, thicker stems, and bigger flowers. More importantly for cannabis, polyploidy increases gene dosage, meaning the number of copies of key biosynthetic genes available for expression.</p><p>As Keating points out, the genes responsible for cannabinoid biosynthesis — THCA synthase and CBDA synthase — are located on chromosome 7 and are present in two copies in a diploid plant. In a tetraploid plant, there may be four.</p><p>“If all four copies are THCA synthase, you’ve got a strong THC producer,” Keating says. “If they’re all CBDA, you’ve got a CBD-dominant plant. Or you can have a mix, which produces a mixed cannabinoid profile.”</p><p>With more copies of these synthase genes available, the plant has a greater capacity to produce cannabinoids and other secondary metabolites, such as terpenes and flavonoids.</p><h4>Where Triploids Create Commercial Value</h4><p>While tetraploids offer enhanced metabolic potential, Keating says triploids are often the commercial end goal.</p><p>Triploid plants are typically sterile or near-sterile, meaning they produce little to no viable pollen or seeds. For cultivators, this can significantly reduce the risk of accidental pollination, one of the most persistent threats to flower quality in commercial facilities.</p><p>“When you remove reproductive pressure,” Keating explains, “the plant can redirect more energy toward resin production and secondary metabolites.”</p><p>That combination of enhanced gene dosage from polyploid breeding and the operational benefits of sterility is why Keating and other advanced breeders believe triploid cannabis could represent the next major leap in cultivation.</p><h4>Where Triploid Breeding Can Go Wrong</h4><p>While triploid cannabis holds significant promise, John Keating cautions that polyploid breeding is inherently unstable if it’s not executed carefully, which is why many efforts fail.</p><p>The first challenge arises at the tetraploid stage. When breeders force a diploid plant (2N) into a tetraploid state (4N), they’re pushing the plant into a condition it does not naturally want to maintain. Cells become larger, chromosome density increases, and unless <em>every</em> cell successfully converts to tetraploidy, the plant can end up as a mixoploid, a mosaic of diploid and tetraploid cells.</p><p>“That mixed state is a problem,” Keating explains. “Because diploidy is the plant’s natural condition, any remaining diploid cells can eventually dominate.” Over time, that instability can cause the plant to revert toward diploidy, undermining the entire breeding effort.</p><p>Gene dosage compounds the risk. Doubling chromosomes increases the</p><p>number of all genes, potentially amplifying undesirable traits. If a plant carries latent issues, such as a tendency toward hermaphroditism, those traits can become more pronounced when additional gene copies are introduced.</p><p>According to Keating, breeders who push lines too aggressively to maintain tetraploidy can also encounter low germination rates, inbreeding depression, and inconsistent phenotypes. The physiological stress of maintaining an enlarged cellular state appears to increase the likelihood that these problems will surface.</p><p>The key, he says, is stabilization.</p><p>Successfully working with polyploid cannabis requires time, repeated selection, and careful environmental management to allow plants to adapt to their new ploidy level.</p><h4>Early Results — and What Still Needs to Be Proven</h4><p>Despite the challenges, Keating says the performance gains he’s seen in commercial settings are incredible.</p><p>According to Keating, triploid cannabis consistently shows increases in potency and yield. While not confirmed, he plans to work with a research university to investigate whether polyploid plants develop thicker trichome walls that could help retain volatile secondary metabolites after harvest.</p><p>“That’s a big deal if true,” Keating says. “Terpenes and other secondary metabolites off-gas hard and fast once the plant is cut. If the trichome structure is physically holding more of that in, that has major implications for post-harvest quality.”</p><p>While that hypothesis still needs peer-reviewed validation, Keating says yield improvements are already showing up clearly at scale.</p><p>“What we’ve seen with the plants we’ve actually released into the world is dramatic increases in yield,” he explains. In multiple large-scale cultivation environments — not just isolated test lights — operators are reporting production levels approaching six pounds per light, a benchmark Keating says he had previously only heard discussed in theory.</p><p>“This isn’t one light or two lights,” he adds. “This is happening across larger facilities.”</p><p>The team plans to enter into clone licensing agreements with major players in different regions and work hand in hand with them. We plan to keep it limited, because we don’t want to flood the market like what happened with Blue Dream. As for seeds, they are producing <a href="https://traplinegenetics.com/">rock-solid batches.</a> We’ve picked our favorite ones that perform across all environments, are high-yielding, and have great appeal.</p><p>For the future, Keating says we will see double haploids, genuine F1s, further polyploidy, and rapid modification via gene editing.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c2e691e4c5dc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[New Study Shows Chromatin Accessibility as Key Factor in Cannabis Potency and Flavor]]></title>
            <link>https://pamchmiel.medium.com/new-study-shows-chromatin-accessibility-as-key-factor-in-cannabis-potency-and-flavor-b09c13a07adb?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/b09c13a07adb</guid>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[scientific-research]]></category>
            <category><![CDATA[cultivation]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Fri, 23 Jan 2026 19:40:33 GMT</pubDate>
            <atom:updated>2026-01-23T19:40:33.156Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*TLsB16Evy4iEx94n_ScIhw.png" /></figure><p>First published in the <a href="https://cannabisindustryjournal.com/feature_article/new-study-shows-chromatin-accessibility-as-key-factor-in-cannabis-potency-and-flavor/">Cannabis Industry Journal</a></p><p>Genetics determines cannabis potency, flavor, and therapeutic value. Choose the right cultivar, stabilize the right traits, and the chemistry will follow. But a new in-depth biological study suggests that genetics may be only part of the equation.</p><p>A recent study published in <a href="https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2025.1687700/full?utm_source=F-NTF&amp;utm_medium=EMLX&amp;utm_campaign=PRD_FEOPS_20170000_ARTICLE"><em>Frontiers in Plant Science</em></a> reveals that chromatin accessibility — an epigenetic mechanism that determines whether genes are “open” or “closed” — can significantly influence cannabinoid and flavonoid production, as well as trichome density, without altering the plant’s DNA. In other words, two genetically identical plants can perform very differently depending on how their genes are expressed.</p><p>These findings highlight a layer of plant biology that could redefine the next frontier in cannabis production.</p><h4>Genetics vs. Epigenetics: Why Some Plants Outperform Others</h4><p>To understand the study’s impact, it helps to distinguish between genetics and epigenetics.</p><ul><li>Genetics determines which genes a plant has</li><li>Epigenetics determines whether those genes are accessible and active</li></ul><p>Chromatin — the structure that packages DNA — can exist in either an “open” or “closed” state. When chromatin is open, transcription machinery can access genes and turn them on. When it’s closed, even high-value genes may remain largely silent.</p><p>The researchers liken this to a cookbook: owning a recipe doesn’t matter if the page is stuck shut.</p><h4>Inside the Study: Comparing High- and Low-Trichome Cannabis</h4><p>The research team analyzed two industrial hemp cultivars with starkly different characteristics:</p><ul><li>One cultivar with dense glandular trichomes</li><li>One cultivar with sparse trichomes and lower secondary metabolite content</li></ul><p>They used an integrated “multi-omics” approach, combining:</p><ul><li>Metabolomics (what compounds the plant actually produces)</li><li>Transcriptomics (RNA-seq) (which genes were expressed)</li><li>ATAC-seq (which regions of the genome were epigenetically accessible)</li></ul><p>The goal: determine not just <em>what</em> differed between the plants, but <em>why</em>.</p><h4>How This Differs From Tissue Culture and Genetic “Cleanup”</h4><p>Tissue culture is already a foundational tool in modern cannabis breeding and propagation. Breeders routinely use micropropagation and meristem culture to eliminate pathogens such as viruses and viroids, stabilize elite cultivars, and preserve valuable genetics over time.</p><p>That process addresses plant health and genetic integrity. Epigenetic regulation, by contrast, addresses plant performance.</p><p>When a cultivar is cleaned through tissue culture, its DNA sequence remains unchanged, but that does not guarantee consistent expression of cannabinoids, flavonoids, or trichome density once the plant is grown at scale. Two plants derived from the same clean mother can still exhibit markedly different chemical profiles depending on how their genes are activated during development.</p><p>This is where the new research adds an important layer of understanding.</p><p>The study shows that chromatin accessibility — an epigenetic mechanism — determines whether key metabolic pathways are actually switched on, even when the underlying genetics are identical and disease-free. In high-performing plants, chromatin surrounding flavonoid biosynthesis and trichome development genes is more “open,” allowing those genes to be expressed at higher levels. In lower-performing plants, the same genes exist but remain less accessible.</p><p>Simply put, tissue culture ensures breeders are starting with a clean, stable genetic foundation. Epigenetics helps explain why that foundation does not always translate into consistent potency, flavor, or secondary metabolite richness in commercial production.</p><p>Rather than replacing tissue culture, epigenetic insights are an opportunity to manipulate a plant’s performance and increase its value. They suggest that the next frontier for breeders and cultivators may lie not only in preserving elite genetics, but also in understanding how cultivation conditions, plant hormones, and developmental cues influence chromatin state and, ultimately, chemical output.</p><h4>Flavonoids: Directly Controlled by Chromatin Accessibility</h4><p>One of the clearest findings involved flavonoids, compounds that contribute to color, aroma, antioxidant activity, and therapeutic nuance.</p><p>In the high-trichome cultivar:</p><ul><li>Chromatin surrounding flavonoid biosynthesis genes was significantly more open</li><li>These genes showed higher expression levels</li><li>Flavonoids such as kaempferol and quercetin derivatives accumulated at much higher levels</li></ul><p>In other words, chromatin accessibility directly governed flavonoid production. When the chromatin opened, the chemistry followed.</p><p>For brands focused on full-spectrum formulations or flavor-forward products, this finding is particularly significant.</p><h4>Cannabinoids: An Indirect Epigenetic Effect</h4><p>Cannabinoid regulation turned out to be more complex.</p><p>While cannabinoid levels (including THC-related compounds and cannabichromene) were higher in the high-trichome cultivar, the chromatin accessibility of the core cannabinoid synthase genes (such as CBDAS and OAC) was not dramatically different between cultivars.</p><p>Instead, epigenetics influenced cannabinoids indirectly by activating pathways that control:</p><ul><li>Fatty acid biosynthesis (key cannabinoid precursors)</li><li>Glandular trichome initiation and density</li><li>Flowering and jasmonate hormone signaling</li></ul><p>The takeaway: epigenetics doesn’t just control the “factory,” it controls the supply chain and factory size.</p><p>More precursors, more trichomes, and greater flowering activity ultimately led to higher cannabinoid accumulation.</p><h4>Trichome Density is a Critical Epigenetic Lever</h4><p>Because cannabinoids are synthesized and stored in glandular trichomes, trichome density is a decisive factor in potency.</p><p>The study found that genes responsible for trichome development — such as <em>GLABRA2</em> — were both:</p><ul><li>More epigenetically accessible</li><li>More highly expressed</li></ul><p>Hormone-responsive genes tied to methyl jasmonate (MeJA), a known trichome stimulant, were also epigenetically activated in the high-performing cultivar.</p><p>This suggests that epigenetic regulation of trichome development may be one of the most powerful levers for increasing cannabinoid yield.</p><h4>Why This Matters for the Cannabis Industry</h4><h4>For cultivators</h4><p>The findings help explain why identical genetics can perform differently across environments. Light spectrum, stress, hormones, and cultivation practices may influence chromatin state — and therefore chemical output.</p><h4>For breeders</h4><p>The study points to epigenetic markers that could complement genetic selection.</p><h4>For brands and formulators</h4><p>This research adds scientific weight to the “entourage effect,” showing that chemical complexity is biologically coordinated rather than accidental. It also supports investment in cultivars bred for consistent metabolite expression, not just headline THC numbers.</p><h4>Cannabis Quality Just Took A Step Up</h4><p>Ultimately, the study reframes cannabis richness as a three-layer system:</p><p>Chromatin accessibility → gene expression → metabolite production.</p><p>Rather than asking only which genes a plant carries, the industry may increasingly need to ask which genes are accessible — and under what conditions.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b09c13a07adb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[BigMike]]></title>
            <link>https://pamchmiel.medium.com/bigmike-f42b7146ffb1?source=rss-1625a0c21dce------2</link>
            <guid isPermaLink="false">https://medium.com/p/f42b7146ffb1</guid>
            <category><![CDATA[plants]]></category>
            <category><![CDATA[agriculture]]></category>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[hydroponics]]></category>
            <category><![CDATA[cannabis]]></category>
            <dc:creator><![CDATA[Pam Chmiel on The Business Of Cannabis]]></dc:creator>
            <pubDate>Tue, 20 Jan 2026 16:45:09 GMT</pubDate>
            <atom:updated>2026-01-20T16:45:09.860Z</atom:updated>
            <content:encoded><![CDATA[<p>He buildt a global cannabis nutrients empire on instict, precision, and unwavering dedication to the plant. Today, his vision for science, genetics, and global expansion is shaping the next frontier.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*nbAPxUz1oNtHMP5wLZjhKg.png" /></figure><p><strong><em>First published in </em></strong><a href="https://mgmagazine.com/business/bigmike-advanced-nutrients-cannabis-cultivation/"><strong><em>mg Magazine</em></strong></a></p><p>He’s called BigMike for a reason. At 6’7″ tall, Michael Straumietis towers over most people, with a big voice, a big personality, and a big rags-to-riches story to match. He founded — and twenty-six years later, still owns and operates <a href="https://advancednutrients.com/">Advanced Nutrients</a>, which sells cannabis-specific products in 122 countries and generates $170 million in annual revenue, making it the largest cannabis nutrients company in the world.</p><p>He’s also got a big heart. After a near-death experience in 2011, Straumietis founded the <a href="https://joinhumanityheroes.org/">Humanity Heroes Foundation</a>, which to date has provided more than $3 million worth of nonperishable essentials to more than 60,000 individuals and families experiencing homelessness across the United States.</p><p><a href="https://mgmagazine.com/business/growing-horticulture/big-mike-advanced-nutrients/">A legendary outlaw grower</a> turned legitimate businessman, mentor, and philanthropist, Straumietis is a larger-than-life icon in the industry. People literally and figuratively look up to him.</p><p>And he’s still blazing new trails. In December, Advanced Nutrients will unveil its latest proprietary blend designed especially for cannabis, a product Straumietis said enhances brix, resin, and terpenes. He’s so convinced of its positive impact on cultivation that he backs the formula with a 100-percent money-back guarantee.</p><p>But the launch represents more than just another formulation debut. It’s part of a larger strategy Straumietis has been building for decades to position Advanced Nutrients for what he believes will be the industry’s most transformative period yet.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/720/1*ayPVi82lodTLNUlNPi_aIQ.png" /></figure><h4>From the ground up.</h4><p>Straumietis began cultivating in 1983, during a pre-legalization period he calls “the Dark Ages.” Years of experimenting with commercially available fertilizers formulated for vegetables, flowers, and other crops left him increasingly frustrated with lackluster growth and disappointing yields that simply didn’t measure up to the potential he saw in his plants.</p><p>“It didn’t make sense to me,” he recalled. “Cannabis is a completely different plant. Why would it need the same nutrients as a cucumber?”</p><p>When he approached the major fertilizer companies to pitch the idea of cannabis-specific nutrients, he met blank stares and slammed doors. Even after California bucked the federal government and legalized medicinal use in 1996, stigma remained strong. No commercial brands wanted to be publicly linked to marijuana.</p><p>“A lot of people were afraid to talk about cannabis during the early days,” Straumietis said.</p><p>Instead of walking away, he dug in. He and a small team devoured plant physiology research and undertook hundreds of experiments with fellow growers. Molecule by molecule, they proved the effectiveness of entirely new nutrient formulas designed to bring out the best in a plant that had been grown in the figurative dark for centuries.</p><p>“Research has always been the backbone of Advanced Nutrients,” Straumietis said. “We knew we needed to dig into the science, so we did.”</p><p>The formulas debuted to an enthusiastic audience, and by the early 2000s, the company employed more than twenty PhD scientists dedicated to understanding the plant at the molecular level. Today, in labs spanning Europe, Colorado, and Canada, the scientific team investigates everything from basic nutrient uptake to cutting-edge genetic modification. Each new product spends roughly three years in research and development before it’s released to the public, because “consistency is everything in cultivation,” Straumietis said.</p><h4>The genetics gamble.</h4><p>Five years ago, Advanced Nutrients extended its quest for perfect consistency to genetics with the acquisition of biotechnology firm <a href="https://www.tesorogenetics.com/">Tesoro Genetics</a>. Since 2018, Tesoro has researched and developed ways to optimize crop yields, nutrient uptake, and metabolite production. Among the company’s primary focuses are gene editing and polyploidy.</p><p>Polyploidy — multiple complete sets of genetic material in a single cell — is rare and usually fatal in animals. But the genetic anomaly is a successful and not uncommon adaptation in plants, where multiplied genes can produce benefits like increased yield and larger flowers or fruit. Induced triploid genetics, wherein plants are artificially encouraged to develop three complete sets of chromosomes, have been used in commercial agriculture for decades to produce crops like seedless watermelons, grapes, and strawberries.</p><p>Researchers have studied and manipulated polyploids in food crops since the early 1900s, but scientists were not aware of its natural occurrence in cannabis until a wild tetraploid strain — a plant with four complete sets of chromosomes — was discovered in India in 2015. Triploidy in wild cannabis, where plants possess three complete chromosome sets, was documented in 2022.</p><p>Straumietis called polyploidy “a game changer hiding in plain sight.”</p><p>So far, the Tesoro division’s research has yielded what Straumietis described as extraordinary results. <a href="https://mgmagazine.com/business/growing-horticulture/how-to-choose-the-right-cannabis-genetics-for-high-yield-harvests/">Triploid cannabis plants</a> produce much heavier yields, display richer terpene and cannabinoid profiles, and resist pollen contamination, he revealed. Growers testing the company’s triploid genetics reported yields of two pounds or more per light, indicating potential to boost bottom lines dramatically.</p><p>“It’s going to change the face of how cannabis is grown,” Straumietis said.</p><p>The team also is experimenting with tetraploids, octoploids (eight chromosome sets) and double haploids (a homozygous single set) to further push the plant’s genetic potential. Each iteration brings new insights about how cannabis can be optimized for flavor, potency, environmental resilience, and stability. The program resembles the kind of long-term scientific research and development traditional agriculture has performed for more than 100 years, and Straumietis is determined to see cannabis catch up.</p><p>He is confident the future of cannabis has never been more exciting as cultivation moves toward plants biologically engineered for performance, consistency, and quality. The transformation is not unlike the one that took place in traditional agriculture during the late twentieth century, he said.</p><p>“Ninety percent of the vegetables we eat today have been gene-edited,” he added. “You’re going to see the same thing in cannabis.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/420/1*j8IYo6ZWN27Ut_WSIPGqQg.png" /></figure><h4>Global growth, rooted in heritage.</h4><p>Ask Straumietis what sets Advanced Nutrients apart, and he’ll tell you it all comes down to mastering micronutrients and applying the right chelates at the right moment in a plant’s life cycle. Most fertilizer brands, he said, stop at the basics.</p><p>“Micronutrients are critical,” he explained. “A lot of companies overlook that, but micronutrients are where the magic is.”</p><p>Iron, for example, plays an unexpectedly major role in cannabis growth. It’s typically categorized as a micronutrient, but in practice, it behaves almost like a secondary macronutrient. One of Advanced Nutrients’ lead scientists, a world-renowned expert whose doctoral thesis explored iron uptake in plants, coordinates a team working to determine not just how much iron cannabis requires but also which chemical form of the element produces the most vigorous growth and potent flowers.</p><p>“We’ve spent years fine-tuning the way the plant feeds,” Straumietis said. “Once you understand what the plant needs and when when to give it what it needs, cultivation completely changes.”</p><p>Much of Straumietis’s professional life has been devoted to defining, refining, and spreading the gospel of optimal cannabis nutrition. But as legalization rapidly spreads worldwide, he spends an increasing amount of his attention on international expansion. The company now sells products in 122 countries, from established European markets to emerging opportunities in the Middle East, Central Asia, and Africa.</p><p>Recently, he attended an agricultural trade show in Dubai, where Advanced Nutrients showcased its products but kept the cannabis connection under wraps. “People knew we were cannabis people, but we didn’t advertise it,” he said. “A lot of attendees approached us about partnering to open manufacturing facilities in the Middle East. It’s going to be a very exciting opportunity to see what happens there.”</p><p>Growing in extreme desert conditions will rely primarily on greenhouses. “They can grow outdoors, but it’s tougher,” he said. “I’ve seen facilities in the desert, and they need shade cloth, swamp coolers, and similar systems. Most likely, we’ll see indoor greenhouse setups, because it’s a medical market and you want tighter control over the plants.”</p><p>Pakistan has been experimenting with hemp cultivation and is considering a medical marijuana program, and India also is showing interest in legalizing the plant. “Some of the best hash in the world still comes from that part of the world,” Straumietis said.</p><p>He recalled a trip to Morocco’s Rif Mountains, where for centuries local families have cultivated the endangered Beldia landrace strain. “It’s sacred. It’s part of their lineage,” he said. “Unfortunately, the lines are beginning to blur since some farmers are growing Romeo next to Beldia, making the original strain washed out.”</p><p>In Straumietis’s opinion, the difference between cultivation in the United States and the rest of the world is “day and night.” In Germany, for example, producers are still in an early development phase. “They’re not even making pre-rolls or gummies yet,” he said. “There’s a whole learning curve that Europe still has to go through.”</p><p>European cultivators are turning to U.S. experts to help them establish standard operating procedures and refine growing techniques. To support the emerging German market, Advanced Nutrients partnered with the European company GrowMotion to develop starter kits designed for social clubs and home growers. The collaboration brings American cultivation expertise to Europe, helping to bridge the knowledge gap.</p><p>Straumietis advises U.S. companies looking to enter <a href="https://mgmagazine.com/business/growing-horticulture/how-international-cultivators-can-tap-into-germanys-cannabis-market/">Germany</a> to understand and connect with the culture. The business landscape is very different, he said: “It’s a very communal mindset in Europe.”</p><p>Although Europe certainly contains well-run commercial facilities, many remain far from optimal. Straumietis estimated the U.S. is five to seven years ahead of the European Union in cultivation and manufacturing capabilities. “Spain, Italy, France, and Germany are the biggest markets, and that’s where commercialization is going to happen,” he said.</p><p>Despite lagging behind North America in cultivation know-how, international markets are the guardians of the industry’s, and the plant’s, history: original landrace strains, the genetic foundation of modern cannabis. “There’s always going to be a demand for landraces,” Straumietis said. “They’re the grandfathered genetics, where everything came from.”</p><p>These heritage varieties, cultivated for generations in regions like Afghanistan, Thailand, and Colombia, possess unique cannabinoid and terpene profiles that modern hybrids struggle to replicate.</p><p>Straumietis hopes landrace strains won’t vanish as commercial breeding accelerates. He’s optimistic about global preservation efforts, pointing to pioneers like Ben Dronkers of Sensi Seeds, who built one of the most diverse genetics libraries in existence.</p><p>“There are still people out there preserving those original genetics,” he said. “And that’s a good thing, because they’re the foundation of everything we’re building today.”</p><p>As legalization spreads, overlooked corners of the world are quietly discovering the benefits of cannabis for both health and economic growth. “Kyrgyzstan is looking at medical cannabis,” Straumietis said. “Kazakhstan — we’ve been selling there for years. Armenia is preparing to launch its medical sector. A lot is happening. Georgia is another Eastern European region where Advanced Nutrients is sold, specifically in the Caucasus, the region formerly part of the Russian Empire.”</p><p>He predicts a new wave of cannabis production will emerge in regions with lower land and labor costs, much like the tea industry expanded in South Africa. “You’re going to see cannabis genetically modified and grown in places like South America and South Africa,” he said. “When I was in Dubai, a representative from Botswana’s government told me they’re interested in moving medical cannabis forward.”</p><p>He added advances in gene editing and agricultural efficiency could reshape <a href="https://mgmagazine.com/business/legal-politics/cannabis-without-borders-global-standards/">global supply chains</a>, despite regulatory and political hurdles.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/720/1*eIHTA1CKQsVX0wHL9J6-Gw.png" /></figure><h4>The rescheduling catalyst.</h4><p>Straumietis sees a global marketplace ready to take off. In this new landscape, brands born in California, the epicenter of cannabis culture in his opinion, finally can reach consumers across state lines and around the world.</p><p>He also believes federal reform is inevitable, predicting the plant’s recategorization from Schedule I to Schedule III in the U.S. could happen as early as 2026. That change — a major modification of federal narcotics law — would open doors to banking, investment capital, and expanded medical research.</p><p>“When [the plant] goes from Schedule I to Schedule III, you’re going to hear the whole world talking about it,” he said. “It will change the market overnight. The landscape of our industry will change as major players enter, creating numerous opportunities for those who wish to exit.”</p><p>He even expects a short-term “mini bubble” as capital floods the market, followed by a correction that will separate serious operators from the rest.</p><p>“After that, things will get normalized,” he said. “They’ll get consolidated or they’ll sell or they’ll go out of business, and only the strong will survive.”</p><p>For Straumietis, decades of investment in research, genetics, and global infrastructure have been building toward this moment. While others may be caught flatfooted when federal prohibition ends, Advanced Nutrients will be positioned with defensible intellectual property, established international distribution, and the scientific credibility that comes from twenty-six years of cannabis-specific research.</p><p>“We’re just at the tip of the iceberg,” he said. “The best and biggest chapter in cannabis history is still ahead.”</p><p>Hear the full interview with BigMike <a href="https://innovating-cannabis-podcast.simplecast.com/episodes/165-bigmikes-next-big-thing-and-global-opportunities">here.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f42b7146ffb1" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>